

May 02, 2017

To,  
Department of Corporate Services,  
BSE Ltd.,  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001.

Ref: Scrip Code: 532296

Dear Sirs,

**Sub:- Board Meeting**

We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations And Disclosures Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Thursday, May 11, 2017 to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the year ended March 31, 2017 and to consider and recommend dividend, if any, on Equity Shares for the year ended March 31, 2017.

The above is for your information.

Thanking you.

Yours faithfully,  
For Glenmark Pharmaceuticals Limited



Harish Kuber  
Company Secretary Compliance Officer

Tel: 4018 9999 / 4018 9879  
Fax: 4018 9986 (Legal & Secretarial Dept)

**Glenmark Pharmaceuticals Ltd.**

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai - 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: [complianceofficer@glenmarkpharma.com](mailto:complianceofficer@glenmarkpharma.com)